Fenimore Asset Management maintained its position in shares of CONMED Co. (NASDAQ:CNMD) during the fourth quarter, according to its most recent 13F filing with the SEC. The hedge fund owned 7,087 shares of the medical technology company’s stock at the end of the fourth quarter. Fenimore Asset Management’s holdings in CONMED were worth $312,000 as of its most recent filing with the SEC.

Shares of CONMED Co. (NASDAQ:CNMD) traded down 1.30% during midday trading on Wednesday, reaching $38.58. The company’s stock had a trading volume of 199,832 shares. The company has a market cap of $1.07 billion and a P/E ratio of 31.62. The stock’s 50-day moving average price is $41.38 and its 200-day moving average price is $47.60. CONMED Co. has a 12-month low of $36.76 and a 12-month high of $60.66.

CONMED (NASDAQ:CNMD) last announced its quarterly earnings results on Wednesday, January 27th. The medical technology company reported $0.52 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.51 by $0.01. On average, analysts expect that CONMED Co. will post $1.67 EPS for the current fiscal year.

The firm also recently declared a quarterly dividend, which was paid on Tuesday, January 5th. Stockholders of record on Tuesday, December 15th were paid a $0.20 dividend. This represents a $0.80 annualized dividend and a dividend yield of 2.07%. The ex-dividend date of this dividend was Friday, December 11th.

Several equities analysts have recently commented on the company. Needham & Company LLC restated a “buy” rating on shares of CONMED in a research note on Monday, November 16th. Leerink Swann reiterated a “buy” rating on shares of CONMED in a research note on Monday, November 16th. Zacks Investment Research upgraded CONMED from a “strong sell” rating to a “hold” rating in a research note on Thursday, November 19th. Deutsche Bank reiterated a “buy” rating on shares of CONMED in a research note on Tuesday, November 17th. Finally, Ladenburg Thalmann upgraded CONMED from a “neutral” rating to a “buy” rating and set a $55.00 target price on the stock in a research note on Monday, October 12th. Three investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average price target of $54.33.

In other news, Director David M. Bronson bought 1,500 shares of the firm’s stock in a transaction that occurred on Friday, December 11th. The shares were purchased at an average price of $41.01 per share, with a total value of $61,515.00. Following the purchase, the director now owns 1,500 shares in the company, valued at $61,515. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

CONMED Corporation is a medical technology company. The Company is engaged in the development, manufacturing and sale on a global basis of surgical devices and related equipment. The Company’s products are used by surgeons and physicians in a variety of specialties, including orthopedics, general surgery, gynecology, neurosurgery and gastroenterology. Its product lines consist of orthopedic surgery, general surgery and surgical visualization. Orthopedic surgery consists of sports medicine instrumentation and small bone, large bone and specialty powered surgical instruments. General surgery consists of a line of endo-mechanical instrumentation for minimally invasive laparoscopic and gastrointestinal procedures, a line of cardiac monitoring products, as well as electrosurgical generators and related instruments. Surgical visualization consists of 2D and 3D video systems for use in minimally invasive orthopedic and general surgery.

12 Month Chart for NASDAQ:CNMD

Receive News & Ratings for CONMED Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CONMED Co. and related companies with MarketBeat.com's FREE daily email newsletter.